Table 5.
Cox hazard regression of the independent overall survival predictors.
| P value | HR∗ | 95% CI∗∗ | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age (≥55 years) | 0.046 | 1.667 | 1.097 | 3.100 |
| Sex (male) | 0.457 | 0.891 | 0.656 | 1.208 |
| Stage (III–IV) | 0.044 | 1.283 | 1.035 | 2.940 |
| Prior adjuvant chemotherapy | 0.037 | 0.892 | 0.481 | 0.994 |
| Lymph node metastasis | 0.147 | 1.514 | 0.865 | 2.650 |
| Liver metastasis | 0.025 | 2.015 | 1.091 | 3.720 |
| Number of metastatic sites (≥2) | 0.038 | 1.248 | 1.036 | 1.846 |
| Duration since diagnosis (≥30 months) | 0.145 | 0.992 | 0.974 | 1.011 |
| Neutropenia after first cycle of FTD/TPI | 0.039 | 0.633 | 1.064 | 2.167 |
| Number of FTD/TPI cycles | 0.002 | 0.769 | 0.664 | 0.891 |
∗HR: hazard ratio; ∗∗CI: confidence interval; FTD/TPI: trifluridine/tipiracil.